VC-backed Constellation Pharmaceuticals rolls out IPO
Cambridge, Massachusetts-based Constellation Pharmaceuticals Inc, a developer of tumor-targeted and immuno-oncology therapies, has raised $60 million for its IPO after pricing its 4 million shares at $15 per share. The stock began trading July 19, 2018 on the NASDAQ under the ticker symbol "CNST." J.P. Morgan, Jefferies and BMO Capital Markets are the lead underwriters. The investors included Cormorant Asset Management, Deerfield Management, Fidelity Management and Research Company, Hillhouse Capital, NS Investment, OrbiMed, Sirona Capital, Venrock Healthcare Partners, The Column Group, Third Rock Ventures, Venrock, SROne, University of California Investment Office, Topspin Partners and Casdin Capital.
19 July 2018•2 mins read
